Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus

“…Indications have not changed dramatically. It is mostly in wellestablished indications where growth is observed, such as allogeneic HCT for AML in CR1 but also ALL, more so with advanced disease than with CR1 patients [26,27]. This might reflect the use of new treatments in ALL, such as bispecific antibodies or drug-conjugated antibodies, allowing relapsed patients access to transplant.…”

“…Allogeneic HCT for MDS also continues to increase by 13% to 2322 patients treated. ALL comprises 16% of allogeneic HCT and showed an increase of 10.6% compared with the previous year [27]. Allogeneic HCT for CLL continues to decrease by 16.5%, a trend continued over the last years.…”

“…The survey using a standardized structure captures the numbers of HCT from highly committed participating teams, divided by indication, donor type, and stem cell source. In the last years with the dramatic increase of cellular therapies, the survey also includes information on cellular therapies with hematopoietic cells for uses other than to replace the hematopoietic system [15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30]. The analysis of the survey data since 1990 shows a continued and constant increase in the annual numbers of HCT and transplant rates for both allogeneic and autologous HCT.…”

A post-stem cell transplant risk score for Philadelphia-negative acute lymphoblastic leukemia

“…10 In a study reported by Aleksandr Lazaryan et al in this issue of Haematologica, the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR) investigated the usefulness of the MRC-ECOG score in a large cohort of patients after SCT (n=1731) all of whom were adults with Ph -ALL. 11 While the standard-risk group had favorable outcomes compared to the intermediate-risk group, the adverse risk group was not clearly inferior using the modified MRC-ECOG score. The analysis of relapse and posttransplant treatment failure revealed that t(8;14), monosomy 7 and complex karyotype were the major important determinants.…”

“…Several aspects of the article by Lazaryan et al 11 are of interest. Post-transplant risk scores differ from those for patients treated with conventional therapy.…”